Silicon Valley celebs chip into $250M round for age-fighting startup Celularity. Placenta-based CAR-Ts on the horizon?
A star-studded Celgene spinout is stepping out today with $250 million in fresh cash to develop its quickly maturing stem cell platform to treat cancer, autoimmune disorders, and ultimately to delay the aging process.
The company, called Celularity, is a New Jersey-based startup co-founded by X-Prize founder Peter Diamandis and ex-Celgene executive Bob Hariri. You might also know these guys as the co-founders of Human Longevity, another age-fighting startup that scored a similarly huge round of startup cash back in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.